Year None202420232022202120202019 2/29/2024 Sagimet Biosciences to Participate in Two Upcoming Investor Conferences 1/25/2024 Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock 1/23/2024 Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock 1/22/2024 Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH Pagination First page « first Previous page ‹ previous Page 1 Current page 2
1/22/2024 Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH